EXHIBIT 8

Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries and joint ventures as of March 31, 2023:

Name of the subsidiary/joint venture	Country of Incorporation	Percentage of Direct/Indirect Ownership Interest
Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.	Malaysia	100%⁽³⁾
Aurigene Oncology Limited (formerly Aurigene Discovery Technologies Limited)	India	100%
Aurigene Pharmaceutical Services Limited	India	100%⁽³⁾
beta Institut gemeinnützige GmbH	Germany	100%⁽⁷⁾
betapharm Arzneimittel GmbH	Germany	100%⁽⁷⁾
Cheminor Investments Limited	India	100%
Cheminor Employees Welfare Trust	India	Refer to below footnote⁽¹³⁾
Chirotech Technology Limited	United Kingdom	100%⁽²⁾⁽⁵⁾
Dr. Reddy’s Research Foundation	India	Refer to below footnote⁽¹³⁾
Dr. Reddy's Employees ESOS Trust	India	Refer to below footnote⁽¹³⁾
Dr. Reddy’s Farmaceutica Do Brasil Ltda.	Brazil	100%
Dr. Reddy’s Laboratories (EU) Limited	United Kingdom	100%⁽⁸⁾
Dr. Reddy’s Laboratories (Proprietary) Limited	South Africa	100%⁽⁸⁾
Dr. Reddy’s Laboratories (UK) Limited	United Kingdom	100%⁽⁵⁾
Dr. Reddy’s Laboratories Canada, Inc.	Canada	100%⁽⁸⁾
Dr. Reddy's Laboratories Chile SPA.	Chile	100%⁽⁸⁾
Dr. Reddy’s Laboratories, Inc.	U.S.A.	100%⁽⁸⁾
Dr. Reddy’s Laboratories Japan KK	Japan	100%⁽⁸⁾
Dr. Reddy’s Laboratories Kazakhstan LLP	Kazakhstan	100%⁽⁸⁾
Dr. Reddy’s Laboratories Louisiana, LLC	U.S.A.	100%⁽¹⁾
Dr. Reddy’s Laboratories Malaysia Sdn. Bhd.	Malaysia	100%⁽⁸⁾
Dr. Reddy’s Laboratories New York, LLC	U.S.A.	100%⁽¹⁾
Dr. Reddy’s Laboratories Philippines Inc.	Philippines	100%⁽⁸⁾
Dr. Reddy’s Laboratories Romania S.R.L.	Romania	100%⁽⁸⁾
Dr. Reddy’s Laboratories SA	Switzerland	100%
Dr. Reddy’s Laboratories Taiwan Limited	Taiwan	100%⁽⁸⁾
Dr. Reddy’s Laboratories (Thailand) Limited	Thailand	100%⁽⁸⁾
Dr. Reddy’s Laboratories LLC	Russia	100%⁽⁸⁾
Dr. Reddy’s Laboratories, LLC	Ukraine	100%⁽⁸⁾
Dr. Reddy’s New Zealand Limited	New Zealand	100%⁽⁸⁾
Dr. Reddy’s S.R.L.	Italy	100%⁽⁹⁾
Dr. Reddy’s Bio-Sciences Limited	India	100%
Dr. Reddy’s Laboratories (Australia) Pty. Limited	Australia	100%⁽⁸⁾
Dr. Reddy’s Laboratories S.A.S.	Colombia	100%⁽⁸⁾
Dr. Reddy’s Research and Development B.V.	Netherlands	100%⁽¹⁰⁾
Dr. Reddy’s Venezuela, C.A.	Venezuela	100%⁽⁸⁾
Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited (from August 19, 2020)	China	100%⁽⁸⁾
DRES Energy Private Limited	India	26%⁽¹²⁾
DRL Impex Limited	India	100%⁽¹¹⁾
Dr. Reddy’s Formulations Limited (from March 11, 2021)	India	100%
Idea2Enterprises (India) Private Limited	India	100%
Imperial Credit Private Limited	India	100%
Industrias Quimicas Falcon de Mexico, S.A. de CV	Mexico	100%
Kunshan Rotam Reddy Pharmaceutical Co. Limited	China	51.33%⁽⁴⁾
Lacock Holdings Limited	Cyprus	100%⁽⁸⁾
Nimbus Health, GmbH (from February 24, 2022)	Germany	100%⁽⁷⁾

Organizational structure (continued)

Name of the subsidiary/joint venture	Country of Incorporation	Percentage of Direct/Indirect Ownership Interest
Promius Pharma, LLC	U.S.A.	100%⁽¹⁾
Reddy Holding GmbH	Germany	100%⁽⁸⁾
Reddy Netherlands B.V.	Netherlands	100%⁽⁸⁾
Reddy Pharma Iberia S.A.U.	Spain	100%⁽⁸⁾
Reddy Pharma Italia S.R.L.	Italy	100%⁽⁶⁾
Reddy Pharma SAS	France	100%⁽⁸⁾
SVAAS Wellness Limited	India	100%

⁽¹⁾

Indirectly owned through Dr. Reddy’s Laboratories, Inc.

⁽²⁾

Entity under liquidation.

⁽³⁾

Indirectly owned through Aurigene Oncology Limited.

⁽⁴⁾

Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as per the Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company’s financial statements.

⁽⁵⁾

Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited.

⁽⁶⁾

Indirectly owned through Lacock Holdings Limited.

⁽⁷⁾

Indirectly owned through Reddy Holding GmbH.

⁽⁸⁾

Indirectly owned through Dr. Reddy’s Laboratories SA.

⁽⁹⁾

Indirectly owned through Reddy Pharma Italia S.R.L.

⁽¹⁰⁾

Indirectly owned through Reddy Netherlands B.V.

⁽¹¹⁾

Indirectly owned through Idea2Enterprises (India) Pvt. Limited.

⁽¹²⁾

Accounted in accordance with IFRS 11, “Joint Arrangements”.

⁽¹³⁾

The Company does not have any equity interests in this entity, but has significant influence or control over it.